Download PDF
Aktuelle Urol 2022; 53(01): 31-36
DOI: 10.1055/a-1399-7718
Übersicht

Aktuelle Entwicklungen in der Therapielandschaft des metastasierten hormonsensitiven Prostatakarzinoms (mHSPC)

Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
Christian Schwentner
Diakonie-Klinikum Stuttgart, Urologische Klinik, Stuttgart
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Trotz umfassender Entwicklungen in der Therapie des fortgeschrittenen Prostatakarzinoms im letzten Jahrzehnt, bestand bei Patienten mit metastasierter hormonsensitiver Erkrankung weiterhin ein Bedarf an gut wirksamen und zugleich gut verträglichen Therapien, die bei einer breiten Patientenpopulation zum Einsatz kommen können.

Seit Anfang 2020 wird nach entsprechender Zulassungserweiterung die Lücke beim metastasierten hormonsensitiven Prostatakarzinom (mHSPC) durch Apalutamid in Kombination mit einer Androgendeprivationstherapie (ADT) geschlossen [1]. Der moderne Androgenrezeptor-Inhibitor zeigte in der Zulassungsstudie TITAN, in der mHSPC-Patienten unabhängig von Risiko, Metastasenlast oder Diagnosezeitpunkt einschlossen wurden, gegenüber Placebo plus ADT eine gute Wirksamkeit und Verträglichkeit, bei gleichzeitig guter Lebensqualität [2].

Abstract

Despite major developments in the therapy of advanced prostate cancer over the past decade, there was still an unmet medical need for efficacious and safe therapies suitable for a wide patient population of patients with metastatic hormone-sensitive disease.

Since its label extension for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) at the beginning of 2020, apalutamide in combination with androgen deprivation therapy (ADT) has filled this gap [1]. The novel androgen receptor inhibitor showed good efficacy and safety in comparison with placebo in the pivotal study TITAN while maintaining quality of life – the study included patients irrespective of risk, disease volume, or time of diagnosis [2].

Schlüsselwörter

mHSPC - Therapieoptionen - Androgenrezeptor-Inhibitor - Apalutamid - TITAN-Studie

Keywords

mHSPC - therapeutic options - androgen receptor inhibitor - apalutamide - TITAN study


Publication History

Article published online:
18 May 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Referenzen

  • 1 Fachinformation Erleada® (Stand November 2020).
    PubMedGoogle Scholar
  • 2 Chi KN, Agarwal N, Bjartell A. et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2019; 381: 13-24
    CrossrefPubMedGoogle Scholar
  • 3 Scher HI, Solo K, Valant J. et al. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS One 2015; 10: e0139440
    CrossrefPubMedGoogle Scholar
  • 4 Mottet N, Van Den Bergh RCN, Briers E. et al. EAU Guidelines on Prostate Cancer. presented at the EAU Annual Congress Barcelona 2019. 2019. ISBN: 978-94-92671-04-2 Abrufbar unter (Letzter Zugriff 07.08.2020): https://uroweb.org/guideline/prostate-cancer/
    Google Scholar
  • 5 Harris WP, Mostaghel EA, Nelson PS. et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6: 76-85
    CrossrefPubMedGoogle Scholar
  • 6 Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Langversion 4.0. Leitlinienprogramm Onkologie. 2016
    PubMedGoogle Scholar
  • 7 James ND, Sydes MR, Clarke NW. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163-1177
    CrossrefPubMedGoogle Scholar
  • 8 Parker C, Gillessen S, Heidenreich A. et al. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: v69-v77
    CrossrefPubMedGoogle Scholar
  • 9 Sweeney CJ, Chen YH, Carducci M. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015; 373: 737-746
    CrossrefPubMedGoogle Scholar
  • 10 Fachinformation Taxotere® (Stand April 2020).
    PubMedGoogle Scholar
  • 11 Clarke NW, Ali A, Ingleby FC. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 2019; 30: 1992-2003
    CrossrefPubMedGoogle Scholar
  • 12 Fachinformation Zytiga® (Stand Oktober 2020).
    PubMedGoogle Scholar
  • 13 Fizazi K, Tran N, Fein L. et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2017; 377: 352-360
    CrossrefPubMedGoogle Scholar
  • 14 Fizazi K, Tran N, Fein L. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019; 20: 686-700
    CrossrefPubMedGoogle Scholar
  • 15 Fizazi K, Scher HI, Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992
    CrossrefPubMedGoogle Scholar
  • 16 Ryan CJ, Smith MR, Fizazi K. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152-160
    CrossrefPubMedGoogle Scholar
  • 17 Sweeney CJ, Chen YH, Liu G. et al. Long term efficacy and QOL data of chemohormonal therapy in low and high volume hormone naïve metastatic prostate cancer: E3805 CHAARTED trial. Ann Oncol 2016; 27: 243-265
    CrossrefPubMedGoogle Scholar
  • 18 Chi KN, Chowdhury S, Bjartell A. et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol 2021; DOI: 10.1200/JCO.20.03488.
    CrossrefPubMedGoogle Scholar
  • 19 Ozguroglu M, Chowdhury S, Bjartell A. et al. Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease. J Clin Oncol 2020; 38 (Suppl. 06) 87
    CrossrefPubMedGoogle Scholar
  • 20 Bjartell AS, Ye D, Agarwal N. et al. Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis. EAU20 Virtual 2020; 41: 556
    PubMedGoogle Scholar
  • 21 Agarwal N, Chowdhury S, Bjartell A. et al. Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane). J Clin Oncol 2020; 38 (Suppl. 06) 82
    CrossrefPubMedGoogle Scholar
  • 22 Chi KN, Thomas S, Gormley M. et al. Androgen Receptor Aberrations in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Apalutamide Plus Androgen Deprivation Therapy in TITAN. Ann Oncol 2019; 30 (Suppl. 05) 883
    PubMedGoogle Scholar
  • 23 Chi KN, Saad F, Chowdhury S. et al. Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies. J Clin Oncol 2020; 38: 5541
    CrossrefPubMedGoogle Scholar
  • 24 Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010; 21: 315-324
    CrossrefPubMedGoogle Scholar
  • 25 Smith MR, Thomas S, Chowdhury S. et al. Androgen Receptor Anomalies and Efficacy of Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer From the Phase 3 SPARTAN Study. Cancer Research 2018; 78 (Suppl. 13) 2605
    CrossrefPubMedGoogle Scholar
  • 26 Thelen P, Gschwend J, Wolff JM. et al. Mechanisms of Resistance in Antihormone Therapies of Advanced Prostate Cancer. Aktuelle Urol 2016; 47: 79-85
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Armstrong AJ, Szmulewitz RZ, Petrylak DP. et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 2019; 37: 2974-2986
    CrossrefPubMedGoogle Scholar
  • 28 Davis ID, Martin AJ, Stockler MR. et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 2019; 381: 121-131
    CrossrefPubMedGoogle Scholar